CPG 7909 injection in combination with chemotherapy in patients with advanced or metastatic non-small cell lung cancer, a randomized, multi-center, controlled, phase 2 study

Trial Profile

CPG 7909 injection in combination with chemotherapy in patients with advanced or metastatic non-small cell lung cancer, a randomized, multi-center, controlled, phase 2 study

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Feb 2009

At a glance

  • Drugs Agatolimod (Primary) ; Carboplatin; Cisplatin; Docetaxel; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 20 Aug 2008 Results published in the Journal of Clinical Oncology.
    • 20 Jun 2007 Pfizer has discontinued the agatolimod development programme in non-small cell lung cancer because of no evidence of additional clinical efficacy compared with standard antineoplastics alone.
    • 26 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top